Scientific Expert, PDT Global Medical Affairs
Baxalta Innovations GmbH, a Takeda company, Vienna, Austria
Vienna, Austria
Peter L. Turecek, Univ.-Doz. Prof. Dr, is Senior Director of Baxalta Innovations GmbH, a Takeda Company, and serves as Scientific Expert working in Vienna, Austria.
Since joining R&D in the pharmaceutical industry in 1989, Dr. Turecek has held management positions in Immuno, ÖIH, Baxter, Baxalta, Shire, and now Takeda in the areas of vaccines, recombinant proteins, downstream processing, plasma fractionation, as well as diagnostics and medical device development and preclinical R&D. His work resulted in more than 1400 patents in 75 patent families, and in more than 150 papers and book articles, the majority in peer reviewed journals.
Dr. Turecek holds a doctorate in biochemistry, a magister pharmaciae degree, and a diploma in business administration. He is an Associate Professor at the University of Vienna and an Honorary Professor at the University of Applied Sciences in Krems, Austria. There and at other universities he acts as a lecturer and guest professor of pharmacology and toxicology, pharmaceutical- and protein-biotechnology, and quality and regulatory affairs issues of the biopharmaceutical industry.
Dr Turecek’s fields of expertise include plasma fractionation and plasma products, protein purification and characterization, drug modification technologies, haemophilia, blood coagulation, pathogen inactivation, diagnostics, and pharmaceutical biotechnology. He represents biopharma to international regulatory authorities such as WHO, EDQM, US-FDA, EMA and to scientific and public organizations and is a frequent speaker at international scientific and academic conferences. He is chairman of the Standards Committee “Haemostaseology” of DIN and past chairman of the Blood Products Committee of BIOSafe Special Biologics Expert Working Group. For more than 20 years and actually he is assigned by the Federal Republic of Austria as a permanent specialist to Groups of Experts Nr. 6 on Biological and Biotechnological Products and Nr. 6B on Human Plasma and Plasma Products of the European Pharmacopoeia.
Sunday, June 23, 2024
10:00 – 10:15 ICT
Tuesday, June 25, 2024
13:45 – 14:45 ICT